EmilyGGreengardMD

Pediatric Hematology & Oncology • Minneapolis, MN

Assistant Professor, Pediatrics, University of Minnesota Medical School

Join to view full profile

Dr. Greengard is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Greengard's full profile

Already have an account?

Office
2450 Riverside Ave Se
East Building Journey Clinic 9e
Minneapolis, MN 55454
Phone+1 612-365-8100

Fax+1 612-365-8101
Is this information wrong?

Education & Training

Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2007 - 2010
McGaw Medical Center of Northwestern UniversityResidency, Pediatrics, 2004 - 2007
Saint Louis University School of MedicineClass of 2004

Certifications & Licensure

MN State Medical License 2010 - 2024
SD State Medical License Active through 2021
PA State Medical License 2007 - 2010
IL State Medical License 2004 - 2008
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Active, not recruiting
Phase 3
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Recruiting
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 1
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2013 Jan 31
Completed
Phase 1, Phase 2
MIBG for Refractory Neuroblastoma and Pheochromocytoma Start of enrollment: 2013 Dec 01
Suspended
Not Applicable
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Start of enrollment: 2013 Sep 03
Completed
Phase 1
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2014 Mar 28
Completed
Phase 1, Phase 2
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Start of enrollment: 2014 May 16
Completed
Phase 1, Phase 2
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Start of enrollment: 2014 Sep 01
Completed
Phase 1
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Start of enrollment: 2015 Dec 11
Completed
Phase 1
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Start of enrollment: 2018 Jan 31
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

14 citations
Long Non-Coding RNA ANRIL as a Potential Biomarker of Chemosensitivity and Clinical Outcomes in Osteosarcoma.
Adam M. Lee, Asmaa Ferdjallah, Elise Moore, Daniel C. Kim, Aritro Nath, Emily Greengard, R. Stephanie Huang> ;International Journal of Molecular Sciences. 2021 Oct 16
3 citations
Population Pharmacokinetics and Exposure-Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies.
Xiaofei Zhou, Diane R. Mould, Ying Yuan, Elizabeth Fox, Emily Greengard, Douglas V. Faller, Karthik Venkatakrishnan> ;Journal of Clinical Pharmacology. 2021 Aug 25
6 citations
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Fo...
Sarah B. Whittle, Katharine Offer, Ryan D. Roberts, Amy K. LeBlanc, Cheryl A. London, Robbie G. Majzner, Alex Yee-Chen Huang, Peter J. Houghton, E. Alejandro Sweet Cor...> ;Pediatric Blood & Cancer. 2021 Jun 16
Multifocal Bone Pain, Fevers, and an Enhancing Clavicular Lesion in an 11-year-old Liberian Boy.
John Scheuer, Alice Lehman, Cynthia R. Howard, Emily Greengard, Alexander A. Boucher> ;Pediatrics in Review. 2021 Mar 1
20 citations
Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic la...
Emily Greengard, Yael P. Mosse, Xiaowei Liu, Charles G. Minard, Joel M. Reid, Stephan D. Voss, Keith D. Wilner, Elizabeth Fox, Frank M. Balis, Susan M. Blaney, Peter C...> ;Cancer Chemotherapy and Pharmacology. 2020 Dec 1
12 citations
Prognostic Factors for Development of Subsequent Metastases in Localized Osteosarcoma: A Systematic Review and Identification of Literature Gaps.
Patrick Basile, Emily Greengard, Brenda J. Weigel, Logan G. Spector> ;Sarcoma. 2020 Mar 18
Henoch-Schönlein Purpura Presenting in Association With Neuroblastoma: A Case Report.
Zineb Alfath, Asmaa Ferdjallah, Emily Greengard, Sabeen K. Askari, Karim Thomas Sadak, Colleen K. Correll> ;Frontiers in Pediatrics. 2020 Feb 28
41 citations
Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).
Navin Pinto, Arlene Naranjo, Emily Hibbitts, Susan G. Kreissman, M. Meaghan Granger, Meredith S. Irwin, Rochelle Bagatell, Wendy B. London, Emily Greengard, Julie R. P...> ;European Journal of Cancer. 2019 May 1
5 citations
The incidence of pediatric malignant soft tissue tumors of the skin and subcutaneous tissue.
Walter Joseph Liszewski, Sheilagh Maguiness, Emily Greengard, Christina Boull> ;Pediatric Dermatology. 2018 Nov 1
25 citations
Molecularly Targeted Therapy for Neuroblastoma.
Emily Greengard> ;Children. 2018 Oct 15
37 citations
A phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma.
Sara E. Fritz, Michael S. Henson, Emily Greengard, Amber L. Winter, Kathleen Stuebner, Una Yoon, Vicki L. Wilk, Antonella Borgatti, Lance B. Augustin, Jaime F. Modiano...> ;Veterinary Medicine and Science. 2016 Jun 6
57 citations
Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone
Nathan Gossai, Megan V. Hilgers, Lynda E. Polgreen, Emily Greengard> ;Pediatric Blood & Cancer. 2015 Jun 1
Join now to see all

Lectures

A phase I/II trial of VX15/2503 in children, adolescents, and young adults with relapsed or refractory solid tumors (ADVL1614).
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019